文献速递中医内科中药与中成药合理使用

口服中药治疗经皮冠状动脉介入术后抑郁障碍的系统评价与Meta分析

Oral Chinese Herbal Medicine for Depressive Disorder in Patients after Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.
PubMed 文献 · Chin J Integr Med · 2019-06-20

该系统评价纳入16项随机对照试验共1443例患者,评估口服中药对冠心病PCI术后抑郁障碍的疗效与安全性。结果显示中药在缓解抑郁症状方面与抗抑郁药相当且副作用更少,联合治疗可能更具优势,但异质性高、样本量小,结论需谨慎解读。

要点

  • 口服中药单用与抗抑郁药疗效相近,但副作用更少。
  • 中药联合抗抑郁药可能优于单用抗抑郁药。
  • 证据质量受样本量小和偏倚风险限制,需谨慎解读。

核心结论

  • 口服中药对PCI术后抑郁症状及术后相关临床症状可能有益。
  • 因样本量小和多数试验存在潜在偏倚,结果需谨慎解释。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、Cochrane Library、CNKI、SinoMed、VIP和Wanfang数据库至2018年8月。
  • 纳入16项随机对照试验,共1443例患者。

主要发现

  • 与单用抗抑郁药相比,中药副作用更少(RR=0.54,95%CI 0.43~0.69,582例患者)。
  • 中药联合抗抑郁药可能优于单用抗抑郁药(MD=-1.03,95%CI -1.81~-0.25,267例患者)。
  • 与安慰剂相比,中药在缓解抑郁症状方面似乎更有优势(MD=-19.00,95%CI -20.02~-17.98,189例患者)。
  • 与PCI术后基础治疗相比,两项试验结果不一致。
  • 中药在缓解胸痛及其他一般临床症状方面似乎更有优势。

临床怎么用

  • 可考虑在标准常规药物治疗基础上加用口服中药以改善PCI术后抑郁症状。
  • 中药单用可能减少抗抑郁药相关副作用,但需结合患者具体情况。
  • 临床决策应结合证据质量谨慎权衡,并关注后续更高质量研究。

局限性

  • 纳入试验样本量小。
  • 多数试验存在潜在偏倚。
  • 异质性普遍较高,可能源于干预措施不同和试验质量低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effectiveness and safety of oral Chinese herbal medicines (CHMs) on post-percutaneous coronary intervention (PCI) patients with depressive disorder in coronary heart disease (CHD). METHODS: A literature search was conducted through databases including PubMed, Cochrane Library, Chinese National Knowledge Infrastructure Databases (CNKI), Chinese Biomedical Literature Database (SinoMed), Chongqing VIP Chinese Science and Technology Periodical Database (VIP) and Wanfang Database up to August 2018. Randomized controlled trials (RCTs) comparing CHMs with placebo or no additional treatments on the basis of standard conventional pharmacological therapies were included. Data extraction, analyses and quality assessment were performed according to the Cochrane standards. RevMan 5.3 software was used to synthesize the results. RESULTS: A total of 16 RCTs enrolling 1,443 participants were included in this systematic review. When compared with antidepressants alone, CHMs showed similar benefits with less side effects [risk ratio=0.54, 95% confidence interval (CI) 0.43 to 0.69, 582 patients]; meanwhile, the combination therapy may have more advantages than antidepressants alone [mean difference (MD)=-1.03, 95%CI-1.81 to-0.25, 267 patients). When identified with placebo, CHMs seem to have more advantages in relieving depressive symptoms (MD=-19.00, 95%CI-20.02 to-17.98, 189 patients). However, when compared with basic treatment of post- PCI, CHMs showed different results in two trials. In terms of post-PCI related clinical symptoms, CHMs seem to have more advantages in relieving chest pain and other general clinical symptoms. However, the heterogeneity in this review was generally high, it may be caused by different interventions used in each trial and the low quality of the trials. CONCLUSIONS: In total, CHMs showed potentially beneficial effects on depressive symptoms and post-PCI related clinical symptoms. However, because of small sample size and potential bias of most trials, this result should be interpreted with caution. More rigorous trials with larger sample size and higher quality are warranted to give high quality of evidence to support the use of CHMs for CHD complicated with depression.

来源:Chin J Integr Med,查看原文。版权归原作者所有。

引用

  1. Xue YJ, Xie Y, Zhao GL, et al. Oral Chinese Herbal Medicine for Depressive Disorder in Patients after Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. Chin J Integr Med. 2019. PMID: 31222629. doi:10.1007/s11655-019-2702-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。